M. Nuland, A. Bergman, H. Rosing, N. Vries, A. Huitema, J. Beijnen
{"title":"恩杂鲁胺及其主要代谢物在真实世界转移性去势抵抗性前列腺癌患者队列中的暴露反应评估","authors":"M. Nuland, A. Bergman, H. Rosing, N. Vries, A. Huitema, J. Beijnen","doi":"10.1002/phar.2339","DOIUrl":null,"url":null,"abstract":"Enzalutamide is an oral agent for the treatment of metastatic castration‐resistant prostate cancer (mCRPC); N‐desmethyl enzalutamide is its active metabolite, which has clinically relevant anti‐androgen capacities similar to enzalutamide, and carboxylic acid enzalutamide is an inactive metabolite. The aim of our study was to investigate the relationship between enzalutamide and N‐desmethyl enzalutamide exposure and treatment response in a real‐world cohort of patients with mCRPC.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer\",\"authors\":\"M. Nuland, A. Bergman, H. Rosing, N. Vries, A. Huitema, J. Beijnen\",\"doi\":\"10.1002/phar.2339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Enzalutamide is an oral agent for the treatment of metastatic castration‐resistant prostate cancer (mCRPC); N‐desmethyl enzalutamide is its active metabolite, which has clinically relevant anti‐androgen capacities similar to enzalutamide, and carboxylic acid enzalutamide is an inactive metabolite. The aim of our study was to investigate the relationship between enzalutamide and N‐desmethyl enzalutamide exposure and treatment response in a real‐world cohort of patients with mCRPC.\",\"PeriodicalId\":19812,\"journal\":{\"name\":\"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/phar.2339\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/phar.2339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer
Enzalutamide is an oral agent for the treatment of metastatic castration‐resistant prostate cancer (mCRPC); N‐desmethyl enzalutamide is its active metabolite, which has clinically relevant anti‐androgen capacities similar to enzalutamide, and carboxylic acid enzalutamide is an inactive metabolite. The aim of our study was to investigate the relationship between enzalutamide and N‐desmethyl enzalutamide exposure and treatment response in a real‐world cohort of patients with mCRPC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
